Cempra to Report Fourth Quarter and Full Year 2016 Financial Results
February 14 2017 - 4:15PM
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in
the treatment of bacterial infectious diseases, today announced
that it will report fourth quarter and full year 2016 financial
results before the open of U.S. financial markets on Tuesday,
February 28, 2017. Cempra management will host a webcast and
conference call at 8:45 a.m. EST that day to discuss the financial
results and provide a corporate update.
The live call may be accessed by dialing
877-377-7553 for domestic callers and 253-237-1151 for
international callers and using conference ID # 71917020. A live
webcast of the call will be available online from the investor
relations section of the company website at www.cempra.com and will
be archived there for 30 days. A telephone replay of the call will
be available by dialing 855-859-2056 for domestic callers or
404-537-3406 for international callers and entering the conference
ID # 71917020.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical
company focused on developing antibiotics to meet critical medical
needs in the treatment of bacterial infectious diseases. Cempra's
two lead product candidates are currently in advanced clinical
development. Solithromycin has been evaluated in two Phase 3
clinical trials for community-acquired bacterial pneumonia (CABP).
Cempra is currently seeking approval for both intravenous and oral
capsule formulations from the U.S. Food and Drug Administration and
the European Medicines Agency. Solithromycin is licensed to
strategic commercial partner Toyama Chemical Co., Ltd., a
subsidiary of FUJIFILM Holdings Corporation, for certain exclusive
rights in Japan. Solithromycin is also in a Phase 3 clinical trial
for uncomplicated urogenital urethritis caused by Neisseria
gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the
development of solithromycin for pediatric use and has commenced
enrollment in a global Phase 2/3 trial to evaluate the safety and
efficacy of solithromycin versus standard of care antibiotics in
children and adolescents from two months to 17 years of age.
Fusidic acid is Cempra's second product candidate, which has
completed enrollment of an initial Phase 3 trial comparing fusidic
acid to linezolid in patients with acute bacterial skin and skin
structure infections (ABSSSI). Cempra also has an ongoing
exploratory study of fusidic acid for chronic oral treatment of
refractory infections in bones and joints. Both products seek to
address the need for new treatments targeting drug-resistant
bacterial infections in the hospital and in the community. Cempra
is also studying solithromycin for ophthalmic conditions and has
synthesized novel macrolides for non-antibiotic uses such as the
treatment of chronic inflammatory diseases, endocrine diseases and
gastric motility disorders. Cempra was founded in 2006 and is
headquartered in Chapel Hill, N.C. For additional information about
Cempra please visit www.cempra.com.
Company Contact:
John Bluth
Cempra, Inc.
+1 984 209 4534
jbluth@cempra.com
Investor Contact:
Robert Uhl
Westwicke Partners, LLC
+1 858 356 5932
robert.uhl@westwicke.com
Media Contact:
Melyssa Weible
Elixir Health PR
+1 201 723 5805
mweible@elixirhealthpr.com
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024